Similarly, we recognized that the consistency of lncRNA as a therapeutic target is also uncertain, and it may vary in different cardiovascular and cerebrovascular diseases mentioned above, such as MEG3, which was up-regulated in Ang-II-treated cardiomyocytes (heart failure) while down-regulated in congenital heart disease. The gene discussed is AGT; the disease is cerebrovascular disorder.